Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting ...
The Company's Board of Directors (the "Board”) approved payment of the $0.0075 per share per month dividend beginning in ...
Palatin Technologies, Inc. (AMEX: PTN) Q2 2025 Earnings Call Transcript February 13, 2025 ...
Universal Security Instruments, Inc. (NYSE AMEX: UUU) today announced results for its fiscal third quarter and nine months ended December 31, 2024.
Q2 2025 Earnings Call Transcript February 6, 2025 Operator: Good day, everyone, and welcome to Lumentum Holdings Second ...
Q2 2025 Earnings Call Transcript February 12, 2025 Aytu BioPharma, Inc. beats earnings expectations. Reported EPS is $-0.26, ...
H1 2024-25 results in line with expectations Operating verticals revenues of €600m up 3.9% like-for-like1 Adjusted EBITDA margin of 55.2% FY 2024-25 objectives confirmed ...
Company reported positive Phase 2b QUALITY study topline results for enobosarm + semaglutide (Wegovy®) with study meeting prespecified primary endpoint of preservation of lean mass as well as greater ...
Operator: Greetings, and welcome to the Great Elm Group Fiscal 2025 Second Quarter Conference Call. At this time, all ...
NeuroOne Medical Technologies Corporation ( NASDAQ: NMTC) Q1 2025 Earnings Conference Call February 12, 2025 8:30 AM ET ...
Good morning, and welcome to the Conference Call for Tate & Lyle's Q3 Trading Statement. Your speakers today are Nick Hampton, Chief Executive; and Sarah Kuijlaars, Chief Financial Officer. I will now ...
The February 2025 Model Shadow Stock Portfolio Update is now available online.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback